KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Capital Expenditures (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Capital Expenditures for 7 consecutive years, with $14.6 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 8905.56% to $14.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.5 million through Dec 2025, up 5585.4% year-over-year, with the annual reading at $70.5 million for FY2025, 5585.4% up from the prior year.
  • Capital Expenditures hit $14.6 million in Q4 2025 for GoodRx Holdings, down from $55.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $55.4 million in Q3 2025 to a low of -$13.7 million in Q2 2023.
  • Historically, Capital Expenditures has averaged $10.4 million across 5 years, with a median of $4.4 million in 2021.
  • Biggest five-year swings in Capital Expenditures: crashed 454.93% in 2021 and later surged 13641.44% in 2025.
  • Year by year, Capital Expenditures stood at $26.1 million in 2021, then tumbled by 42.04% to $15.1 million in 2022, then dropped by 17.68% to $12.5 million in 2023, then crashed by 98.7% to $162000.0 in 2024, then surged by 8905.56% to $14.6 million in 2025.
  • Business Quant data shows Capital Expenditures for GDRX at $14.6 million in Q4 2025, $55.4 million in Q3 2025, and $390000.0 in Q2 2025.